# Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

> **NCT00189540** · PHASE2 · COMPLETED · sponsor: **AnGes USA, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Arterial Occlusive Disease
- Peripheral Vascular Disease
- Ischemia
- Ulcers

## Interventions

- **GENETIC:** HGF plasmid
- **GENETIC:** Placebo

## Key facts

- **NCT ID:** NCT00189540
- **Lead sponsor:** AnGes USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-07
- **Final completion:** 2008-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189540, "Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00189540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*